KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema In addition to this therapeutic expertise, KalVista has a management team with proven experience in bringing small molecules through the clinic to commercialisation and as a result has attracted significant financial backing from leading life science investors, SV Life Sciences and Novo Ventures